ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2019

Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy?

Juan Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.